NPPA sets Ceiling Price for Gufic Meropenem Dual Chamber Bag

The National Pharmaceutical Pricing Authority (NPPA) has handed a special ceiling price for the product of Meropenem Powder for Injection in dual chamber bags by Gufic Biosciences Limited which is 15% more than the existing one in recognition of its unique product features.

The revised ceiling price was determined as Rs. 845.94 per dual chamber bag for Meropenem Powder for Injection 500 mg and Rs. 1114.72 per dual chamber bag for the 1000 mg strength with no inclusion of GST.

Gufic Biosciences has been requesting a separate ceiling price for its dual chamber bag formulations specifying the uniqueness of the product that it is self-collapsible, self-sealable, free from an air vent, and has zero contamination risk during manufacture, infusion, or admixing. These properties make the product very different from the traditional packaging and increase safety and usability.

Also Read: Sun Pharma & Lupin to develop affordable anti-obesity pills

Despite the fact that Meropenem 500 mg and 1000 mg (as trihydrate) are listed under Schedule-I of the Drugs (Prices Control) Order, 2013 (DPCO, 2013) with a defined ceiling price, NPPA took into account the request made by the company after it had been referred to the Multidisciplinary Committee of Experts and reviewed in its 69th and 70th meetings held on July 3 and August 5, 2025.

The committee recommended a 15% higher ceiling price that would reflect the innovation, which was later confirmed by NPPA at its 136th Authority meeting on August 28, 2025. This step is believed to be quite encouraging for the development of innovative critical care drugs while at the same time ensuring patient safety and affordability.